Patient 4 was initially diagnosed with a primary tumor that had the BRAF V600E mutation and underwent treatment with FOLFIRI plus cetuximab as the first-line chemotherapy (Figure 2G & H). The gene discussed is BRAF; the disease is neoplasm.